Summit Therapeutics SMMT Non-cash interest expense
Discontinued — last reported Q4 '25
Non-cash interest expense at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept smmt:InterestExpenseIncomeNoncash.
The official record: Summit Therapeutics’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's non-cash interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's non-cash interest expense?
- Summit Therapeutics (SMMT) reported non-cash interest expense of $0 in Q4 2025.
- What is the long-term trend for Summit Therapeutics's non-cash interest expense?
- Over 3 years (2022 to 2025), Summit Therapeutics's non-cash interest expense has grown at a -100.0% compound annual growth rate (CAGR), from $4.39M to $0.
- What does non-cash interest expense mean?
- Non-cash interest costs that affect accounting profit but not actual cash balances.
- How do you interpret non-cash interest expense?
- Higher values suggest significant non-cash financing costs, which may indicate complex debt structures.
- How does non-cash interest expense compare across companies?
- Common in companies with significant long-term debt or convertible notes.